This is an exciting time for leukemia treatment, with multiple new therapies being approved and various agents on the horizon. At the International Conference of Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), Ravindra Majeti, MD, PhD, from Stanford University, Stanford, CA, discusses why he is enthusiastic about novel treatments against leukemia and details the improvements required to move this treatment forwards.
